Status:

COMPLETED

PET-MR for Prediction and Monitoring of Response to Neoadjuvant Chemotherapy in Breast Cancer

Lead Sponsor:

Seoul National University Hospital

Collaborating Sponsors:

Ministry of Health & Welfare, Korea

Conditions:

Breast Cancer

Eligibility:

FEMALE

18-70 years

Brief Summary

The purpose of this study is: To validate the efficacy of multiparametric MRI, FDG-PET, RGD-PET, and PET-MR fusion imaging in the prediction and monitoring response to neoadjuvant chemotherapy of loc...

Detailed Description

Enrolled women with breast cancers who had received an anthracycline-taxane regimen and subsequent surgery were prospectively enrolled. DCE-MRI and FDG-PET scan were performed before and after the 1st...

Eligibility Criteria

Inclusion

  • Pathologically confirmed breast cancer
  • Clinical stage IIb, IIIa, IIIb, IIIc
  • Must have measurable disease
  • Performance status of ECOG 0-2
  • Adequate, bone marrow, liver, heart, and renal function
  • Who did not receive chemotherapy for breast cancer
  • Must agree with and signed informed consent

Exclusion

  • Prior history of cancer besides breast cancer
  • Active bacterial infection
  • Pregnant or lactating women
  • Psychological disease or seizure
  • History of arrhythmia, congestive heart failure, myocardial infarct, or unstable angina
  • Male breast cancer
  • Who had a pacemaker or history of open heart surgery

Key Trial Info

Start Date :

May 1 2010

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

May 1 2013

Estimated Enrollment :

57 Patients enrolled

Trial Details

Trial ID

NCT01190566

Start Date

May 1 2010

End Date

May 1 2013

Last Update

July 7 2015

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Seoul National University Hospital

Seoul, South Korea, 110-744